Biodextris

Process Development Service in Laval, Quebec 

Looking for Process Development Services for Biotech Manufacturing?

Our expert team provides tailored solutions for biotech manufacturing, including upstream and downstream process development,
tech transfer, and process validation. Designed for pharmaceutical and biotech companies, we ensure efficiency, scalability, and compliance at every stage


Process Development

Biodextris is an expert in accelerating our client’s projects from the bench to the clinic. We efficiently deliver robust and reliable production processes ready for manufacturing a wide array of vaccines and biologics. We offer comprehensive process development activities for complex biological products in the following areas:

  • Recombinant purified proteins
  • Cell membrane preparations
  • Complex multi-component systems
  • Whole cell based products
  • Monoclonal antibodies

Our clients span the globe as well as sectors from agricultural applications, to diagnostics and of course our cores in human health-based biologics and vaccines.


Throughout the execution of our process development strategy, our analytical services team develop appropriate assays to ensure your product is properly characterized and enumerated accurately, insuring the product meets or exceeds your expectations. Click here for more details about our Analytical Method Development.

Upstream Process

Biologics are produced via a variety of methods and all sorts of microorganisms (bacteria, yeast, fungi and eukaryotic cells), and at Biodextris, we are experts with many of the species used in industry. From the beginning, we aim to identify and control the key process parameters that will provide your product with the optimal set of critical quality attributes.


Biodextris can be your guide navigating through the following activities in establishing an upstream process:

  • Media evaluation
  • Host strain evaluation
  • Cell line development
  • Development of batch or fed-batch protocols
  • Product optimization strategies (yield increase, reducing undesired product)
  • Analytical parameters

We develop your upstream process using industry leading pilot-scale fermenters and bioreactors. Our systems are interfaced for continuous monitoring, control and data acquisition of temperature, pH, agitation, airflow, pressure, dissolved oxygen, exhaust gas (O2/CO2) and nutrient feeds all in a GMP cleanroom environment where applicable.

Book an Appointment

Downstream Purification

Many see downstream purification as a mixture of art and craft, however, at Biodextris we make it science! We have extensive experience separating our clients’ target products from complex matrices by developing, assessing and optimizing a downstream purification strategy. With our expertise and equipment, we effectively isolate your product while preserving its identity, purity, potency and homogeneity. Our comprehensive analytical group work in tandem to ensure all these parameters are properly analyzed and documented.

We will lead you through phase-appropriate activities such as resin screening, chromatographic protocol development, protein compatibility studies, accelerated stability studies, process robustness and pre-formulation testing leading to a comprehensive downstream package ready for manufacturing.

We use industry leading AKTA Avant and Pilot systems for performance of various chromatography methods including ion exchange, hydrophobic interaction, reverse phase and size exclusion chromatography as well as tangential flow filtration and sterile filtration.

Book an Appointment

Process Transfer

At Biodextris, we can supply material for early stage clinical trials, but with a client’s success come larger scale needs. Our team is well equipped to transfer your production process to a large-scale partner cGMP facility. We have extensive experience with small and medium sized biotechnology companies, large pharmaceutical and large vaccine manufacturers, government organizations and CMOs. Biodextris is truly an international organization having a well-versed multicultural team and clients across Canada, USA and Europe and Asia.


Our expertise helps our clients contain costs, manage risk and maintain key process knowledge. We employ a systematic approach to process transfer that includes the following:

  • Control scale-related process variations
  • Control equipment related variations
  • Management and execution of transfer lots
  • Comprehensive training
  • Knowledge management.
Book an Appointment

Your Health And Safety Is Important To Us

Get in Touch With Us

Drop us a Message

Please feel welcome to contact our friendly reception staff with any enquiry. We will answer to you shortly!

Development Service - Contact Us

Recent Articles

Tips, News and Updates

Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman to Lead Global Commercial Expansion

By Philippe Beland • June 11, 2025
Biodextris Appoints Dr. Behzad Mahdavi as Executive Chairman & Chief Commercial Officer Who: Dr. Behzad Mahdavi, Ph.D., MBA, NACD.DC — a biopharma industry veteran with over 25 years of senior leadership experience in CDMO and CRO sectors, including roles at Lonza and Catalent. What: He has been appointed Executive Chairman and will additionally serve as Chief Commercial Officer at Biodextris. Why: Dr. Mahdavi will spearhead the company’s global commercial expansion, leveraging his expertise in commercial innovation and international market development About Biodextris: Headquartered in Laval (Montréal), Québec, Biodextris is a rising Contract Development & Manufacturing Organization (CDMO) specializing in biologics and vaccine development, rooted in the legacy of GSK’s biologics and supported by ArchiMed private equity. For full details, you can read the original PR Newswire article here: https://www.prnewswire.com/news-releases/biodextris-appoints-dr-behzad-mahdavi-as-executive-chairman-to-lead-global-commercial-expansion-302472664.html

Aramis Biotechnologies and Biodextris Announce Partnership

December 17, 2024
Quebec City, December 17th, 2024 – Aramis Biotechnologies Inc. ("Aramis"), a Quebec City-based company specialized in plant-based biomanufacturing of innovative vaccines, and Biodextris Inc. (“Biodextris”), a Montreal-based CDMO specialized in cGMP complex biologic products, are excited to announce the signature of an agreement. This strategic partnership will leverage the expertise of both companies to ensure efficient downstream manufacturing of clinical materials for Aramis’ leading product candidate, a seasonal influenza vaccine with the potential to improve the protection of at-risk populations. Under the terms of the agreement, Biodextris will provide Aramis with access to its state-of-the-art facilities and industry-leading capabilities to ensure the timely production of high-quality materials for Aramis’ forthcoming Phase 1 & 2 clinical trials. The downstream manufacturing agreement marks an important milestone in the ongoing collaboration between Aramis and Biodextris, combining cutting-edge science and manufacturing excellence to drive success in clinical development. "We are delighted to be working with Biodextris as partner for downstream manufacturing and supply of clinical material" said Aramis’ Co-founder & CEO, Frédéric Ors. "This partnership is aligned with Aramis’ business model to use the best external expertise and capabilities, and prepare operations scale-up for potential pandemic response. From the initial proposal through to the extensive collaboration to date, we’ve been impressed by Biodextris’ partnership-centric approach to identifying and solving technical challenges, as well as their commitment to the highest quality standards, making them an ideal partner for clinical-scale production of our influenza vaccine candidate.” "It’s a pleasure to be chosen as Aramis’ development and downstream manufacturing partner in their mission to revolutionize vaccines” says Cédric Héroux, Biodextris’ GM. “The Aramis team’s deep scientific expertise and passion for health impact, both in Canada and at a global level, has resonated deeply with Biodextris since the start of our collaboration, and we look forward to working with them to make these vaccines accessible to patients.” About Aramis Biotechnologies Based in Quebec City, Aramis Biotechnologies is a Canadian company founded in 2023 that specializes in plant-based production of innovative vaccines. As a majority employee-owned company, our ambition is to develop innovative and sustainable solutions to current and future public health challenges. The Aramis’ team is grateful for the support from Innovation, Sciences and Economic Development Canada and from the City of Quebec. About Biodextris Inc. Biodextris is a cGMP complex biologics CDMO with over 20 years’ experience in the development, GMP manufacturing, and bioanalysis of high-value complex biologic products. With customers ranging from the largest global Biopharmaceutical companies to university spin-outs, Biodextris is the partner of choice for innovative Biotechnology companies with novel or complex processes looking to accelerate their path to clinic & commercialization. Biodextris’ new center of excellence in Laval, supporting customers in manufacturing and analysis from pre-clinical development through to commercialization, was developed with the support of the governments of Quebec and Canada, as well as Investissement Québec. For more information: aramisbiotechnologies.com biodextris.com

Aramis Biotechnologies et Biodextris annoncent un partenariat

December 17, 2024
Québec, le 17 décembre 2024 - Aramis Biotechnologies Inc. (« Aramis »), une entreprise de Québec spécialisée dans la production de vaccins innovants produits dans les plantes, et Biodextris Inc. (« Biodextris »), un CDMO de Montréal spécialisé dans les produits biologiques complexes conformes aux BPF, sont heureux d'annoncer la signature d'une entente. Ce partenariat stratégique s'appuiera sur l'expertise des deux sociétés pour assurer une fabrication en aval efficace du matériel clinique pour le produit candidat principal d'Aramis, un vaccin contre la grippe saisonnière ayant le potentiel d'améliorer la protection des populations à risque. Selon les termes de l'accord, Biodextris fournira à Aramis l'accès à ses installations de pointe et à ses capacités industrielles de premier plan afin d'assurer la production en temps voulu de matériel de haute qualité pour les prochains essais cliniques de phase 1 et 2 d'Aramis. L'accord de fabrication en aval marque une étape importante dans la collaboration en cours entre Aramis et Biodextris, combinant science de pointe et excellence de la production pour assurer le succès du développement clinique. « Nous sommes ravis de travailler avec Biodextris en tant que partenaire pour la fabrication en aval et l’approvisionnement de matériel clinique », a déclaré Frédéric Ors, cofondateur et chef de la direction d'Aramis. « Ce partenariat s'inscrit dans le modèle d’affaires d'Aramis, qui consiste à utiliser les meilleures compétences et capacités externes, et à préparer la mise à l’échelle des opérations en vue d'une éventuelle réponse à une pandémie. Depuis la proposition initiale jusqu'à la collaboration approfondie à ce jour, nous avons été impressionnés par l'approche centrée sur le partenariat de Biodextris pour identifier et résoudre les défis techniques, ainsi que par son engagement à respecter les normes de qualité les plus élevées, ce qui en fait un partenaire idéal pour la production à l'échelle clinique de notre candidat-vaccin contre la grippe. » « C'est un plaisir d'être choisi comme partenaire d'Aramis pour le développement et la fabrication en aval dans sa mission de révolutionner les vaccins », déclare Cédric Héroux, directeur général de Biodextris. « L'expertise scientifique approfondie de l'équipe d'Aramis et sa passion pour l'impact sur la santé, tant au Canada qu'au niveau mondial, ont trouvé un écho profond auprès de Biodextris depuis le début de notre collaboration, et nous sommes impatients de travailler avec eux pour rendre ces vaccins accessibles aux patients. » À propos d’Aramis Biotechnologies Basée à Québec, Aramis Biotechnologies est une entreprise canadienne fondée en 2023 qui se spécialise dans la production de vaccins innovants produits dans les plantes. En tant qu’entreprise à capital majoritairement détenu par nos employés-actionnaires, notre ambition est de développer des solutions novatrices et durables pour répondre aux défis de santé publique actuels et futurs. L'équipe d'Aramis est reconnaissante du soutien apporté par Innovation, Sciences et Développement économique Canada et par la Ville de Québec. À propos de Biodextris Inc. Biodextris est un CDMO de produits biologiques complexes conformes aux BPF avec plus de 20 ans d'expérience dans le développement, la fabrication BPF et la bioanalyse de produits biologiques complexes de grande valeur. Avec des clients allant des plus grandes sociétés biopharmaceutiques mondiales aux entreprises dérivées d’universités, Biodextris est le partenaire de choix pour les sociétés de biotechnologie innovantes avec des processus nouveaux ou complexes qui cherchent à accélérer leur chemin vers la clinique et la commercialisation. Le nouveau centre d'excellence de Biodextris à Laval, qui soutient les clients dans la fabrication et l'analyse depuis le développement préclinique jusqu'à la commercialisation, a été développé avec le soutien des gouvernements du Québec et du Canada, ainsi que d'Investissement Québec. Pour plus d’informations: aramisbiotechnologies.com biodextris.com

FAQs

Got a question? We’re here to help.

  • Where is your main office?

    The office is located in Laval